This proposal is the second renewal of our originally funded Fogarty International Center application (D43 TW005884) entitled, Training and Research in Severe Malarial Anemia and the additional program we established with supplemental funding entitled, Expanding Research on Severe Malarial Anemia to Include Training and Research in the Areas of HIV/Malaria Co-Infections. The International Malaria Training and Research Program (IMTRP) was established in 2002 (Perkins, PD/PI). During the last cycle of funding, the trainees were highly prolific generating 23 peer-reviewed manuscripts (3 in press) and 52 presentations at international meetings. Based on the highly successful nature of our activities, we plan to continue training endemic area scientists in state-of-the art technologies and quantitative analyses in genetics and molecular immunology. In addition, we will expand our training platform to meet the growing demands of the scientific community in Kenya and internationally. The expanded program will include training in drug and vaccine discovery and biostatistics. Our strategic approach for training relies on previous and ongoing success in genetics that have identified a number of important genes and gene pathways that influence severe malarial anemia (SMA) which will now guide the development of novel treatment options. Engagement of trainees in drug and vaccine discovery comes at an opportune time since the treatment and management of SMA around the globe has been met with very limited success. Moreover, an essential requirement for success in all scientific arenas is biostatistics, yet there is a critical shortage of biostatisticians in sub-Saharan Africa. This challenge will be directly addressed by providing long-term training in this important area. The three scientific focus areas selected for training (genetics and molecular immunology, drug and vaccine discovery, and biostatistics) will be supported by internationally recognized experts at the University of New Mexico (UNM) and at our long-standing (10 years) partner sites in Kenya, Kenyatta University, Maseno University, and Kenya Medical Research Institute (KEMRI). Collectively, the training platform will be supported by more than $35 million in annual direct funding by the Faculty Mentors. In the renewal application, we propose to provide training for three doctoral students who are currently completed their MSc programs with support from the IMTRP. In addition, we propose to provide postdoctoral training for one Kenyan mentee that is completing his PhD and two postdoctoral fellows (per year) that will spend 11 months per annum on-site at UNM receiving state-of-the-art training in the one of the three focus areas. Since we are now in the fortunate position of having trained some members of the IMRTP from the doctoral level through completion of their postdoctoral fellowships, we will expand our activities to include long-term training of junior faculty. We propose to provide support for two junior faculty members per year as the trainees matriculate and procure faculty positions at either Kenyatta or Maseno Universities. In addition to the long-term training described, we will also provide medium-term training by having an equal representation of the Kenyan junior faculty, postdoctoral, and doctoral mentees spend three months per year at UNM for specialized training in one of the three focus areas (3 per year). Lastly, we will provide short-term, in-depth training to junior faculty, postdoctoral fellows, doctoral and medical students, and masters'level trainees through annual workshops that focus on (1) genetics and molecular immunology (2) drug and vaccine discovery (3) epidemiology and biostatistics (4) pathogenesis and hematology (5) clinical management of pediatric infectious diseases and (6) bioethics. The short-term training will take place at the KEMRI research facility in western Kenya and will be taught by scientific experts from the US and Kenya. The overall training paradigm designed in the renewal application will ensure that all trainees in the IMTRP receive the required technical and intellectual expertise to conduct independent research for the control and prevention of malarial anemia and other pediatric infectious diseases. Continuation of our highly successful training program will also provide the necessary technology transfer and capacity building required for establishing a critical mass of Kenyan scientists to address the challenging public health problems facing their society.
In the proposed continuation of our research training program, we have assembled a multidisciplinary team of investigators from the US and Kenya to provide training in three scientific target areas (1) genetics and molecular immunology (2) drug and vaccine discovery and (3) biostatistics. These focus areas were strategically selected so that our long-, medium, and short-term training plans for endemic area scientists can provide important capacity building in Kenya and achieve maximal impact for the prevention and management of their public health challenges.
|Ogutu, Bernhards R; Onyango, Kevin O; Koskei, Nelly et al. (2014) Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J 13:33|
|Anyona, Samuel B; Kempaiah, Prakasha; Davenport, Gregory C et al. (2013) Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia. Biochem Biophys Res Commun 436:585-90|
|Okeyo, Winnie A; Munde, Elly O; Okumu, Wilson et al. (2013) Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels. BMC Immunol 14:15|
|Ouma, Collins; Davenport, Gregory C; Garcia, Steven et al. (2012) Functional haplotypes of Fc gamma (Fcýý) receptor (FcýýRIIA and FcýýRIIIB) predict risk to repeated episodes of severe malarial anemia and mortality in Kenyan children. Hum Genet 131:289-99|
|Ong'echa, John M; Raballah, Evans O; Kempaiah, Prakasha M et al. (2011) Polymorphic variability in the 3' untranslated region (UTR) of IL12B is associated with susceptibility to severe anaemia in Kenyan children with acute Plasmodium falciparum malaria. BMC Genet 12:69|
|Awandare, Gordon A; Kempaiah, Prakasha; Ochiel, Daniel O et al. (2011) Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model. Am J Hematol 86:155-62|
|Were, T; Davenport, G C; Hittner, J B et al. (2011) Bacteremia in Kenyan children presenting with malaria. J Clin Microbiol 49:671-6|
|Ong'echa, John M; Davenport, Gregory C; Vulule, John M et al. (2011) Identification of inflammatory biomarkers for pediatric malarial anemia severity using novel statistical methods. Infect Immun 79:4674-80|
|Anyona, Samuel B; Kempaiah, Prakasha; Raballah, Evans et al. (2011) Functional promoter haplotypes of interleukin-18 condition susceptibility to severe malarial anemia and childhood mortality. Infect Immun 79:4923-32|
|Phawong, Chintana; Ouma, Collins; Tangteerawatana, Piyatida et al. (2010) Haplotypes of IL12B promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults. Immunogenetics 62:345-56|
Showing the most recent 10 out of 23 publications